P1NP, β-crosslaps and osteocalcin as biochemical markers of bone turnover in haemodialysis patients

被引：0
|
作者：
Tesija-Kuna, A [1 ]
Vrkic, N [1 ]
Pavlovic, D [1 ]
Topic, E [1 ]
机构：
[1] Univ Zagreb, Sestre Milosrdnice Univ Hosp, Zagreb, Croatia
来源：
CLINICAL CHEMISTRY | 2005年 / 51卷
关键词：
D O I：
暂无
中图分类号：
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号：
1001 ;
摘要：
引用
收藏
页码：A243 / A243
页数：1
相关论文
共 50 条
  • [1] P1NP, b-CrossLaps and osteocalcin as biochemical markers of bone turnover in haemodialysis patients
    Pavlovic, D
    Vrkic, N
    BONE, 2005, 36 : S237 - S238
  • [2] Serum Osteocalcin, P1NP, Alkaline Phosphase, and CrossLaps in Humans The relationship with body mass index
    Carsote, Mara
    Preda, Smaranda Adelina
    Mitroi, Mihaela
    Camen, Adrian
    Radu, Lucretiu
    REVISTA DE CHIMIE, 2019, 70 (05): : 1615 - 1618
  • [3] Markers of bone turnover in haemodialysis patients
    Grzegorzewska, Alicja E.
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2006, 21 (12) : 3602 - 3603
  • [4] Reliability of the Biochemical Bone Markers CTX and P1NP during a TNF-Inhibitor Treatment Cycle in Patients with Rheumatoid Arthritis
    Holmsted, Kim
    Jorgensen, Niklas Rye
    Madsen, Ole Rintek
    ARTHRITIS & RHEUMATOLOGY, 2017, 69
  • [5] Markers of bone turnover in haemodialysis patients - Reply
    Albalate, Marta
    Caramelo, Carlos
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2006, 21 (12) : 3604 - 3604
  • [6] THE AMINO-TERMINAL PROPEPTIDE (P1NP) IS A CLINICALLY VALID INDICATOR OF BONE TURNOVER IN PROSTATE CANCER PATIENTS
    Oertl, A.
    Klepzig, M.
    Jonas, D.
    Oremek, G. M.
    ANTICANCER RESEARCH, 2011, 31 (05) : 1997 - 1997
  • [7] Osteocalcin as a biochemical marker of bone turnover
    Polak-Jonkisz, D
    Zwolinska, D
    NEPHROLOGY, 1998, 4 (5-6) : 339 - 346
  • [8] EFFECT OF DENOSUMAB ON BONE FORMATION MARKER P1NP
    Tanigawa, H.
    Maeda, T.
    Kumagai, K.
    Imai, S.
    OSTEOARTHRITIS AND CARTILAGE, 2018, 26 : S89 - S89
  • [9] Relationship between P1NP, a biochemical marker of bone turnover, and bone mineral density in patients transitioned from alendronate to romosozumab or teriparatide: a post hoc analysis of the STRUCTURE trial
    Junichi Takada
    Rajani Dinavahi
    Akimitsu Miyauchi
    Etsuro Hamaya
    Toshiyasu Hirama
    Cesar Libanati
    Yoichi Nakamura
    Cassandra E. Milmont
    Andreas Grauer
    Journal of Bone and Mineral Metabolism, 2020, 38 : 310 - 315
  • [10] EFFECT OF DENOSUMAB ON BONE FORMATION MARKER P1NP
    Tanigawa, H.
    Tanemura, M.
    Nakajima, R.
    Tamagawa, Y.
    Imai, S.
    OSTEOPOROSIS INTERNATIONAL, 2019, 30 : S97 - S97
12345